SCHEMBL2945006

SCHEMBL2945006

COc1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(NC(=O)C3CCC(N(C)C)CC3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ F10 P00742 5/20 0.40
▸ GSK3B P49841 4/20 0.40
▸ DYRK1A Q13627 4/20 0.40
▸ WNT1 P04628 2/20 0.40
▸ MEN1 O00255 5/20 0.39
▸ KMT2A Q03164 5/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ MAPT P10636 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ DEGS1 O15121 1/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944999 1.00 SMN1; SMN2 (0.41) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2942803 0.92 SMN1; SMN2 (0.39) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2942805 0.92 SMN1; SMN2 (0.39) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL13290965 0.92 SMN1; SMN2 (0.41) SMN1; SMN2F10MEN1KMT2AHSD17B10
SCHEMBL2953852 0.91 F10 (0.42) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2953859 0.91 F10 (0.42) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2945544 0.90 F10 (0.44) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2945536 0.90 F10 (0.44) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2947646 0.90 SMN1; SMN2 (0.43) SMN1; SMN2F10GSK3BDYRK1AWNT1
SCHEMBL2947653 0.90 SMN1; SMN2 (0.43) SMN1; SMN2F10GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US claimed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US claimed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US claimed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP claimed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-20060094724-A1 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-05-04 — — US disclosed
EP-1582521-A1 FUSED FURAN COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2005-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885F10 4/4885GSK3B 4638/4885
US-20060094724-A1 Fused furan compound F2, F12, F11 SMN1; SMN2 4490/4885F10 4/4885GSK3B 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback